After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Climb Bio Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Climb Bio Inc is $142.98M. A total of 1.65 million shares were traded on the day, compared to an average of 384.54K shares.
In the most recent transaction, Brennan Aoife sold 20,618 shares of CLYM for 1.22 per share on Jun 30 ’25. After the transaction, the President and CEO now owns 48,132 company shares. In a previous transaction on Jun 20 ’25, Pimblett Emily sold 1,242 shares at 1.24 per share. CLYM shares that SVP, Finance & CAO owns now total 18,888.
Among the insiders who sold shares, Pimblett Emily disposed of 1,199 shares on Mar 20 ’25 at a per-share price of $1.31. This resulted in the SVP, Finance & CAO holding 15,130 shares of CLYM after the transaction. In another insider transaction, Pimblett Emily sold 1,235 shares at $2.02 per share on Dec 19 ’24. Company shares held by the CHIEF ACCOUNTING OFFICER now total 11,329.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, CLYM has a high of $8.79 and a low of $1.05.
As of this writing, CLYM has an earnings estimate of -$0.15 per share for the current quarter. EPS was calculated based on a consensus of 4.0 estimates, with a high estimate of -$0.13 per share and a lower estimate of -$0.17. The company reported an EPS of -$0.13 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. CLYM’s latest balance sheet shows that the firm has $136.48M in Cash & Short Term Investments as of fiscal 2021. There were $0.00 in debt and $6.03M in liabilities at the time. Its Book Value Per Share was $2.74, while its Total Shareholder’s Equity was $167.20M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CLYM is Buy with a score of 4.60.
